For
the past decade, Dr. Brasel has focused on the development and
evaluation of medical countermeasures, including vaccines, for emerging
and biological defense-related infectious diseases. He has played key
roles in the advancement of vaccine candidates against plague, anthrax,
tularemia, smallpox, and most recently, hemorrhagic fevers caused by
Ebola and Marburg viruses. Throughout his career, Dr. Brasel has focused
on advanced product development under the United States Food and Drug
Administration (FDA) Animal Rule (21 CFR 601.90) which allows efficacy
findings from adequate and well-controlled animal studies to be used in
cases where it is not feasible or ethical to conduct trials in humans.
Search PubMed for Dr. Brasel's publications